Descriptive Analyses of Clinical Characteristics and Treatment Patterns of Breast Cancer Patients Initiating Palbociclib (Ibrance®) Treatment in the US Community Oncology Setting

First published 14/12/2016

Last updated 02/07/2024

EU PAS number:

EUPAS16710

Study

Finalised

Documents

Study protocol

Initial protocol

Ibrance EMR utilization study NI Study Protocol 03 December 2015 Final (Clean)

English (793.86 KB - PDF)View document

Study results

A5481067 Abstract

English (153.83 KB - PDF)View document

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Conflicts of interest of investigators

A5481067

English (2.31 MB - PDF)View document

Secondary tabs